ISRCTN45741714已完成不适用
Effect of transdermal testosterone replacement in hypogonadal men with decreased insulin sensitivity
ProStrakan Pharmaceuticals (UK)0 个研究点目标入组 320 人开始时间: 2006年2月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1.Hypogonadal males
- •2.Decreased insulin sensitivity
排除标准
- •1.Use of testosterone replacement therapy in the last six months
- •2.History of or current prostate carcinoma
研究者
相似试验
进行中（未招募）
不适用
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus - TIMES 2Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass and strength and sexual dysfunction. A number of conditions can also be associated with decreased testosterone production including metabolic syndrome, type II diabetes mellitus, atherosclerosis, myocardial infarction and chronic heart failureEUCTR2005-002607-17-DEProstrakan Pharmaceuticals Ltd520
进行中（未招募）
不适用
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes MellitusEUCTR2005-002607-17-ITSTRAKAN PHARMACEUTICALS LIMITED320
进行中（未招募）
1 期
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus - TIMES 2Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass and strength and sexual dysfunction. A number of conditions can also be associated with decreased testosterone production including metabolic syndrome, type II diabetes mellitus, atherosclerosis, myocardial infarction and chronic heart failureEUCTR2005-002607-17-GBProstrakan Pharmaceuticals Ltd520
进行中（未招募）
不适用
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus - TIMES 2EUCTR2005-002607-17-BEProStrakan Ltd520
进行中（未招募）
1 期
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes MellitusEfecto de la terapia sustitutiva de testosterona transdérmica en hombres hipogonadales o con síndrome metabólico o con diabetes mellitus tipo 2 - TIMES 2Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass and strength and sexual dysfunction. A number of conditions can also be associated with decreased testosterone production including metabolic syndrome, type II diabetes mellitus, atherosclerosis, myocardial infarction and chronic heart failureEUCTR2005-002607-17-ESStrakan Pharmaceuticals Ltd530